| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9931838 | The Journal of Pain | 2005 | 8 Pages |
Abstract
Preclinical data have shown ultralow-dose opioid antagonists to enhance and prolong opioid analgesia while reducing analgesic tolerance and physical dependence. Recent molecular pharmacology data show a mechanism of action to be the prevention of aberrant G protein coupling by opioid receptors that underlies opioid tolerance and dependence.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Vishala L. Chindalore, Richard A. Craven, K. Peony Yu, Peter G. Butera, Lindsay H. Burns, Nadav Friedmann,